Dr reddy lab
-
Upload
nirankar-royal -
Category
Education
-
view
2.130 -
download
5
description
Transcript of Dr reddy lab
DRL CASE STUDYPrepared by –
Astha Bishnoi
Ashutosh Ranjan
Diksha Uniyal
Nikhil Sharma
Nirankar Royal
Swimmi Alaska
Basis of success of DRL prior to mid-90s
Reverse Engineering Variant of new drug at low cost Process innovation Speed
Looking at drug which have high growth and less sensitive to price fluctuation like anti-ulcerants
Indian patent act, DCPO were favorable Two pronged approach towards export
Exported to countries where patents had expired DRL adopted the route of exporting penultimate
stage intermediates for bulk drugs
Contd:
Weak intellectual property rights which facilitated reverse engineering
Methyldopa – choice of product and timing of entry
Foreign exchange regulation act Compare to US & Europe, production cost is less
in India Produce bulk drugs where margin was good In 1990, dropping of anti-dumping charges which
resulted in publicity Exploitation of HW act (ANDA)
Started research programs by investing 4% of revenue Molecular restructuring Set up new drug development research
(NDDR)
Post mid 90s
Focus on two different segments Capacity expansion Building brands
Manufacture generics going off patent and innovator tie-ups
Distribution system was reorganized Joint ventures in foreign markets
Countries with high population Per capita consumption of medicines is high Proximity to markets in near by countries e.g. Egypt,
Brazil Drug patent law not strongly in force
Contd:
Acquisition of brands instead of company for short-term growth
Tied-up with US firms for exporting drugs Fully owned subsidiary in US Marketing join ventures in Brazil Co-marketing and development
agreement with Par Pharmaceuticals
Contd:
Drug discovery – focus on creating a lead molecule (NCE) and selling it.
DRL acquired ARL because of which it got five complementary brand, 3 manufacturing plants & 450 trained field staff.
Licensed to multi-nationals for clinical trials and marketing
Focused on areas of growing concern like diabetes and cancer
Contd:
Intermediate and Bulk Drug Substances
Commodity Generics
Conventional Dosage Forms
Value added and Branded Generics
OTC and NDDS
Post TRIPs Era
Should focus more on R&D for new chemical entities (NCE)
U.S. FDI compliant to harness the growth opportunity in areas of contract manufacturing and research as US$45 billion of drugs would go off patent by 2007 in us alone
Increase in U.S. ANDA fillings Exploring new markets Tie-up with foreign companies to in-license drugs Acquisition to become big firm – Roche’s API
business, Betapharm
R & D expenditure of DRL
2005 2006 2007 2008 20090
5
10
15
20
25
30
35
40
number
number
Patents granted in USPTA
UPTO 2004
2005 2006 2007 2008 20090
10
20
30
40
50
60
number
number
ANDA Fillings
UPTO 2004
2005 2006 2007 2008 20090
10
20
30
40
50
60
ANDA fillings
number
THANK YOU